GRI Bio Inc. (GRI)vsRevolution Medicines Inc (RVMD)
GRI
GRI Bio Inc.
$2.00
-6.10%
HEALTHCARE · Cap: $3.98M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. GRI earns a higher WallStSmart Score of 26/100 (F).
GRI
Avoid26
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GRI
The strongest argument for GRI centers on P/E Ratio, Price/Book, Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : GRI
The primary concerns for GRI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
GRI is growing revenue faster at 0.0% — sustainability is the question.
GRI generates stronger free cash flow (-4M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GRI scores higher overall (26/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRI Bio Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
GRI Bio Inc. is an innovative biotechnology firm dedicated to transforming patient care through its proprietary microbiome technology platform. The company focuses on developing groundbreaking therapies aimed at addressing unmet medical needs in immunology and oncology, prioritizing the treatment of disease causes over mere symptom management. With a comprehensive pipeline of product candidates and strategic research collaborations, GRI Bio is strategically positioned to emerge as a leader in the expanding microbiome therapeutics sector. Its commitment to improving patient outcomes underscores its potential to make substantial contributions to the evolution of healthcare solutions.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?